SYDNEY and NASHVILLE, Tenn.,
June 29,
2023 /PRNewswire/ -- IVFAustralia, an
Australian-based provider of full-service fertility care, IVF and
related services as part of the Virtus Health network, and
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a
leading global provider of innovative temperature-controlled supply
chain solutions supporting the life sciences, reproductive medicine
and animal health industries, today announced that IVFAustralia has
selected Cryoport as its exclusive supply chain solutions partner
for its global reproductive material shipments.
The multi-year agreement provides IVFAustralia and its fertility
patients with the most advanced cryogenic shipping service in the
world. Cryoport's ISO-certified risk mitigation process ensures
safe, end-to-end transport of reproductive materials across the
entire Virtus Health network.
"IVFAustralia is at the forefront of innovations that ensure
risk mitigation for our patients," said Kate Munnings, CEO of Virtus Health. "Always
employing the latest technologies and in keeping with the Fertility
Society of Australia and
New Zealand's issued
recommendations around advanced data logging, chain of custody and
condition monitoring that should be followed while transporting
cryopreserved gametes and embryos, we have chosen Cryoport as our
exclusive supply chain solutions provider. Its scientifically
engineered shippers enable state-of-the-art GPS monitoring,
internal temperature tracking and 24/7 logistics monitoring that
meet the guidelines of the most rigorous regulatory agencies."
Jerrell Shelton, CEO of Cryoport,
continued, "IVFAustralia is the first full-service fertility care
company in Australia to embrace
our best-in-class technology for safely transporting valuable
reproductive materials for families around the globe. IVFAustralia
is part of Virtus Health, the largest provider of fertility
services in Australia and, with a
growing presence in Singapore,
Ireland, the United Kingdom and Denmark, our selection is a true testament to
Cryoport's ability to provide the highest-quality services for
fertility patients everywhere. We look forward to working closely
with IVFAustralia to ensure that that every detail, from start to
finish, is handled with the utmost care and protection it
deserves."
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in
temperature-controlled supply chain solutions for the life sciences
industry supporting life-saving cell and gene therapies across the
research, clinical and commercial spectrum. With 48 strategic
locations covering the Americas, EMEA (Europe, the Middle
East and Africa) and APAC
(Asia Pacific), Cryoport's global
platform provides mission-critical solutions, services, and
products to the biopharma/pharma, animal health, and reproductive
medicine markets worldwide. In addition to its standard setting
supply chain solutions, Cryoport is the world's largest
manufacturer of cryogenic systems and one of the largest life
science focused specialty couriers.
For more information, visit www.cryoport.com or follow @cryoport
on Twitter at www.twitter.com/cryoport for live updates.
About Virtus Health
Virtus Health Limited brings together leading clinicians,
scientists, researchers and support staff to provide the very best
in fertility care, IVF and related services. The company is the
largest provider of fertility services in Australia, Ireland & Denmark with a growing presence in
Singapore & the United Kingdom. Brands within the Virtus
Health group include Queensland Fertility Group, IVFAustralia,
Melbourne IVF, TasIVF, The Fertility Centre, Sims IVF, Complete
Fertility, Trianglen Clinic, Aagaard Fertility Clinic and Virtus
Fertility Centre in Singapore.
Forward-Looking Statements
Statements in this press release which are not purely
historical, including statements regarding the Company's
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, plans, strategy, acquisitions,
financial results and financial condition. It is important to note
that the Company's actual results could differ materially from
those in any such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, risks and uncertainties associated with the effect of
changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
discussed in the Company's Securities and Exchange Commission
("SEC") reports including, but not limited to, the Company's Annual
Report on Form 10-K for the three and twelve months ended
December 31, 2022 and any subsequent
filings with the SEC. The forward-looking statements contained in
this press release speak only as of the date hereof and the Company
cautions investors not to place undue reliance on these
forward-looking statements. Except as required by law, the Company
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ivfaustralia-selects-cryoport-as-exclusive-supply-chain-solutions-provider-301866948.html
SOURCE Cryoport, Inc.